MCID: HYP014
MIFTS: 51

Hyperuricemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 73 54 44 15 17 70
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 44 D033461
NCIt 50 C3961
SNOMED-CT 67 271198001
ICD10 32 E79.0
UMLS 70 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to tubulointerstitial kidney disease, autosomal dominant, 1 and glycogen storage disease ia, and has symptoms including seizures, muscle weakness and polydipsia. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Selenium Micronutrient Network and Cori Cycle. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and endothelial, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 73 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 519)
# Related Disease Score Top Affiliating Genes
1 tubulointerstitial kidney disease, autosomal dominant, 1 32.5 UMOD SLC2A9 SLC22A12 REN HPRT1 HNF1B
2 glycogen storage disease ia 32.3 SLC2A9 INS G6PC1
3 lesch-nyhan syndrome 32.3 XDH SLC2A9 SLC22A12 SLC17A3 SLC17A1 HPRT1
4 autosomal dominant tubulointerstitial kidney disease 32.1 UMOD REN HNF1B
5 gout 31.7 XDH UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1
6 acute kidney failure 31.1 UMOD SLC22A12 REN GPT
7 chronic kidney disease 31.0 UMOD REN INS HNF1B CRP APOB
8 urolithiasis 31.0 XDH UMOD HPRT1
9 kidney disease 30.9 XDH UMOD REN INS HNF1B CRP
10 coronary heart disease 1 30.9 INS CRP APOB
11 lipid metabolism disorder 30.9 INS GGT1 CRP APOB ADRB3
12 nephrolithiasis 30.8 XDH UMOD SLC2A9 SLC22A12 INS HPRT1
13 fatty liver disease 30.8 INS GPT GGT1 APOB
14 hypercholesterolemia, familial, 1 30.8 INS GPT CRP APOB
15 interstitial nephritis 30.6 UMOD REN CRP
16 vascular disease 30.6 XDH REN INS CRP APOB
17 end stage renal disease 30.6 UMOD REN INS CRP APOB
18 autosomal dominant tubulointerstitial kidney disease - ren 30.6 UMOD REN
19 glycogen storage disease 30.5 SLC17A3 PFKM INS G6PC1 CRP
20 arteries, anomalies of 30.5 REN INS CRP APOB
21 hyperglycemia 30.5 INS HNF1B G6PC1 APOB
22 glucose intolerance 30.5 INS GPT CRP ADRB3
23 hypouricemia, renal, 1 30.4 SLC2A9 SLC22A12 HPRT1
24 non-alcoholic fatty liver disease 30.4 INS GPT GGT1 CRP APOB
25 arteriosclerosis 30.4 INS GPT CRP APOB
26 hypothyroidism 30.3 REN INS GPT CRP APOB
27 hyperthyroidism 30.3 INS GPT CRP
28 cerebrovascular disease 30.3 REN INS CRP APOB
29 polycystic kidney disease 30.3 UMOD SLC22A12 REN INS HNF1B
30 uremia 30.3 REN INS CRP
31 pyelonephritis 30.2 UMOD GPT CRP
32 deficiency anemia 30.2 XDH INS HPRT1 GPT CRP
33 body mass index quantitative trait locus 11 30.1 REN INS GPT GGT1 G6PC1 CRP
34 urinary tract infection 30.1 UMOD CRP
35 autosomal dominant polycystic kidney disease 30.1 SLC22A12 REN INS HNF1B
36 abdominal obesity-metabolic syndrome 1 30.1 INS APOB ADRB3
37 chronic pyelonephritis 30.1 UMOD REN CRP
38 hypertension, essential 30.0 XDH UMOD SLC2A9 SLC22A12 REN INS
39 vesicoureteral reflux 1 30.0 UMOD REN CRP
40 nephrolithiasis, uric acid 30.0 XDH SLC2A9 SLC22A12 HPRT1
41 inherited metabolic disorder 29.7 REN INS GPT G6PC1 CRP APOB
42 beta-thalassemia 29.7 INS GPT CRP APOB
43 type 2 diabetes mellitus 29.7 SLC2A9 REN INS HNF1B GPT GGT1
44 liver cirrhosis 29.7 REN INS GPT GGT1 G6PC1 CRP
45 lipoprotein quantitative trait locus 29.7 REN INS GPT CRP APOB
46 acute pancreatitis 29.7 INS GPT CRP
47 diabetes mellitus 29.6 UMOD REN INS HNF1B GPT GGT1
48 sleep apnea 29.6 REN INS GPT CRP APOB
49 cardiovascular system disease 29.4 XDH REN INS GGT1 CRP APOB
50 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 11.5

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


seizures; muscle weakness; polydipsia; fever; dyspnea; vertigo; cachexia; headache; syncope; cyanosis; edema; icterus; signs and symptoms; signs and symptoms, digestive; hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.07 ADRB3 APOB G6PC1 GGT1 HNF1B HPRT1
2 homeostasis/metabolism MP:0005376 10.03 ABCG2 ADRB3 APOB CRP G6PC1 GGT1
3 immune system MP:0005387 9.73 ABCG2 APOB CRP GGT1 HNF1B HPRT1
4 renal/urinary system MP:0005367 9.36 ABCG2 G6PC1 GGT1 HNF1B HPRT1 INS

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
3
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
4
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
9
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
10
Rasburicase Approved, Investigational Phase 4 134774-45-1
11
Canagliflozin Approved Phase 4 842133-18-0
12
Febuxostat Approved Phase 4 144060-53-7 134018
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
16
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
17
Rosemary Experimental Phase 4
18
Cobalamin Experimental Phase 4 13408-78-1 6857388
19
Uric acid Investigational Phase 4 69-93-2 1175
20
Quercetin Experimental, Investigational Phase 4 117-39-5 5280343
21
Benzbromarone Investigational, Withdrawn Phase 4 3562-84-3 2333
22 Trace Elements Phase 4
23 Nutrients Phase 4
24 Vitamin B9 Phase 4
25 Micronutrients Phase 4
26 Folate Phase 4
27 Vitamins Phase 4
28 Vitamin B Complex Phase 4
29 Calciferol Phase 4
30 Vitamin B 12 Phase 4
31 Vitamin B12 Phase 4
32 Hormones Phase 4
33 Hormone Antagonists Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 glucocorticoids Phase 4
36 Angiotensin-Converting Enzyme Inhibitors Phase 4
37 Antihypertensive Agents Phase 4
38 Diacetylrhein Phase 4
39 insulin Phase 4
40 Insulin, Globin Zinc Phase 4
41
protease inhibitors Phase 4
42 Sodium Chloride Symporter Inhibitors Phase 4
43 Estradiol 3-benzoate Phase 4
44 Estradiol 17 beta-cypionate Phase 4
45 Estrogens Phase 4
46 diuretics Phase 4
47 HIV Protease Inhibitors Phase 4
48 Progestins Phase 4
49 Pharmaceutical Solutions Phase 4
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
2 Effect of Multi-vitamins With Minerals on Uric Acid Metabolism in Subjects With Hyperuricemia: A Randomized, Double-blinded, Placebo-controlled Trail Unknown status NCT03218709 Phase 4
3 Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
4 A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome Completed NCT00651911 Phase 4 urate oxidase
5 Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
6 Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
7 Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
8 Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
9 Evaluation of the Effects of a Supplement Composed by Quercetin, Rutin, Bromelain and L-carnosine in Patients With Hyperuricemia, a Randomized Clinical Trial Completed NCT04161872 Phase 4 Uricemin;Placebo
10 Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
11 Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease Completed NCT00230217 Phase 4 Rasburicase (SR29142)
12 Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome. Completed NCT00302653 Phase 4 Rasburicase
13 A Double-blind, Placebo-controlled, Cross-over Study of the Effects of Allopurinol on Oxidative Metabolism, Peripheral Blood Flow and Immune Function in Patients With Advanced Chronic Heart Failure (CHF). Completed NCT00997542 Phase 4 Allopurinol;Placebo
14 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Completed NCT02956278 Phase 4 Allopurinol
15 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
16 The Cardiovascular Effects of Febuxostat and Benzbromarone on Left Ventricle Diastolic Dysfunction in Individuals With Metabolic Syndrome and Hyperuricemia - an Open-label Non-blinded Randomized-controlled Clinical Trial Recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
17 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double-Blinded, Randomized Controlled Trial Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
18 An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia Active, not recruiting NCT04349306 Phase 4 RASBURICASE SR29142
19 Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors Active, not recruiting NCT02462421 Phase 4 Canagliflozin
20 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
21 Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia Unknown status NCT02282683 Phase 2, Phase 3 prednisone
22 A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout. Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
23 A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
24 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study) Completed NCT03372200 Phase 3 FYU-981;Febuxostat
25 Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
26 Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
27 Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study) Completed NCT03006445 Phase 3 FYU-981
28 Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2) Completed NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
29 Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs) Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
30 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study) Completed NCT03100318 Phase 3 FYU-981;Benzbromarone
31 Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept Recruiting NCT04012294 Phase 3 Allopurinol Pill
32 A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
33 Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam
34 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2 Marine active
35 Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery. Completed NCT00756964 Phase 2 Rasburicase;Placebo
36 Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome Completed NCT01157936 Phase 2 Allopurinol
37 Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome Completed NCT00628628 Phase 2 As Needed Rasburicase;Fixed Dose Rasburicase
38 A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy Completed NCT01265264 Phase 2 ulodesine;Placebo
39 Sarcoma Alliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas Completed NCT00401388 Phase 2 Perifosine
40 Open-label, Multicenter Study of Repeated Doses of SR29142 (Rasburicase) as a Uricolytic Therapy for Hyperuricemia in Adult Patients With Leukemia or Lymphoma. Completed NCT00631579 Phase 2 Rasburicase (SR29142)
41 Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia Completed NCT02837198 Phase 2 FYU-981;Topiroxostat
42 A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Febuxostat Compared With Tranilast Alone and Febuxostat Alone in Healthy Subjects With Hyperuricemia Completed NCT00995618 Phase 2 Tranilast;Febuxostat;Combination - Tranilast and Febuxostat
43 A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment Completed NCT01082640 Phase 2 Febuxostat;Placebo
44 A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout Completed NCT01336686 Phase 2 Arhalofenate;Arhalofenate;Placebo comparator;Colchicine
45 Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00741442 Phase 2 RDEA806;Placebo
46 Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study) Completed NCT02416167 Phase 2 FYU-981;Placebo
47 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout Completed NCT00955981 Phase 2 RDEA594;Placebo
48 A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Allopurinol Compared With Tranilast Alone and Allopurinol Alone in Healthy Subjects With Hyperuricemia Completed NCT01052987 Phase 2 Tranilast;Allopurinol;Combination - Tranilast and Allopurinol;400 mg Allopurinol;High dose combination
49 A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout Completed NCT01416402 Phase 2 Arhalofenate;Febuxostat;Colchicine
50 A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout Completed NCT02252835 Phase 2 Arhalofenate;Febuxostat;Arhalofenate;Febuxostat;Colchicine

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Mannitol hexanitrate
Rasburicase

Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

40
Kidney, Heart, Endothelial, Liver, Bone, Thyroid, Brain

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 7318)
# Title Authors PMID Year
1
Childhood course of renal insufficiency in a family with a uromodulin gene mutation. 54 61
20151160 2010
2
Uric acid transport and disease. 61 54
20516647 2010
3
Uric acid as a factor in the metabolic syndrome. 61 54
20424936 2010
4
Glomerulocystic kidney: one hundred-year perspective. 54 61
20367310 2010
5
[Association between the risk factors of cardiovascular diseases and insulin resistance]. 61 54
20513276 2010
6
Trp64Arg polymorphism of the ADRB3 gene predicts hyperuricemia risk in a population from southern Spain. 61 54
20008926 2010
7
Allopurinol, xanthine oxidase, and cardiac ischemia. 54 61
19794315 2009
8
Uric acid concentrations are associated with insulin resistance and birthweight in normotensive pregnant women. 61 54
19729142 2009
9
Serum uric acid is associated with metabolic risk factors for cardiovascular disease in the Uygur population. 61 54
20029511 2009
10
Myelination disturbance in a patient with hyperuricemia and hyperserotoninemia combined with 18q deletion syndrome. 54 61
20025132 2009
11
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. 61 54
20109996 2009
12
Utility of waist-to-height ratio in detecting central obesity and related adverse cardiovascular risk profile among normal weight younger adults (from the Bogalusa Heart Study). 61 54
19699351 2009
13
Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. 61 54
19565499 2009
14
Febuxostat (Uloric) for chronic treatment of gout. 61 54
19448587 2009
15
Increased xanthine oxidase in the skin of preeclamptic women. 54 61
19196876 2009
16
Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. 54 61
19413186 2009
17
Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. 54 61
19057528 2009
18
Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. 54 61
18060751 2008
19
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. 61 54
18635756 2008
20
[Uromodulin mutation and hyperuricemia]. 54 61
18409531 2008
21
[Inhibitors of xanthine oxidoreductase]. 61 54
18409526 2008
22
[Primary hyperuricemia due to decreased renal uric acid excretion]. 54 61
18409514 2008
23
[New antihyperuricemic medicine: febuxostat, Puricase, etc]. 54 61
18409528 2008
24
[Uricosuric agent]. 61 54
18409525 2008
25
[Relationship between hyperuricemia and metabolic syndrome]. 61 54
18409529 2008
26
Control of renal uric acid excretion and gout. 54 61
18349750 2008
27
In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). 61 54
18292110 2008
28
Substrate orientation in xanthine oxidase: crystal structure of enzyme in reaction with 2-hydroxy-6-methylpurine. 61 54
18063585 2008
29
Uric acid: a surrogate of insulin resistance in older women. 61 54
18082342 2008
30
Diabetes and nephrolithiasis. 61 54
18255008 2007
31
Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. 54 61
18067674 2007
32
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy]. 54 61
18071212 2007
33
Thiazide diuretics exacerbate fructose-induced metabolic syndrome. 61 54
17855639 2007
34
The metabolic syndrome in hypertension: diagnostic and therapeutic implications. 54 61
17686382 2007
35
The association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor. 61 54
17225053 2007
36
Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. 61 54
17512306 2007
37
Prevalence of the metabolic syndrome in individuals with hyperuricemia. 54 61
17466656 2007
38
Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. 61 54
17449420 2007
39
Association between silent ST segment depression in exercise electrocardiography and insulin resistance in obese subjects. 54 61
17552288 2007
40
Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? 61 54
17278928 2007
41
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. 61 54
19075968 2007
42
Hypoxanthine-guanine phosphoribosyltransferase deficiency: biochemical and molecular findings in six Argentine patients. 61 54
17454734 2007
43
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. 61 54
17132810 2006
44
Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. 61 54
16920156 2006
45
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). 61 54
17119268 2006
46
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. 61 54
16708061 2006
47
New developments in clinically relevant mechanisms and treatment of hyperuricemia. 54 61
16901081 2006
48
[An analysis of islet beta-cell function in hyperuricemia]. 61 54
16831320 2006
49
Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage. 54 61
16778751 2006
50
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 61 54
16507884 2006

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

Pathways related to Hyperuricemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.89 XDH INS GGT1 CRP APOB
2 10.46 INS GPT
3 10.1 SLC2A9 SLC22A12 SLC17A3 SLC17A1 ABCG2
4 9.98 XDH SLC22A12 HPRT1

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 XDH UMOD REN INS GPT GGT1
2 apical plasma membrane GO:0016324 9.17 UMOD SLC2A9 SLC22A12 SLC17A3 SLC17A1 PFKM
3 brush border membrane GO:0031526 9.13 SLC22A12 SLC17A3 ABCG2

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.78 UMOD SLC22A12 REN HNF1B
2 response to lipopolysaccharide GO:0032496 9.71 UMOD REN GGT1 APOB
3 glycogen catabolic process GO:0005980 9.49 PFKM G6PC1
4 phosphate ion transport GO:0006817 9.46 SLC17A3 SLC17A1
5 glucose-6-phosphate transport GO:0015760 9.43 SLC17A3 G6PC1
6 organic anion transport GO:0015711 9.43 SLC22A12 SLC17A3 ABCG2
7 sialic acid transport GO:0015739 9.37 SLC17A3 SLC17A1
8 urate transport GO:0015747 9.35 SLC2A9 SLC22A12 SLC17A3 SLC17A1 ABCG2
9 response to carbohydrate GO:0009743 9.33 HNF1B G6PC1 APOB
10 GMP catabolic process GO:0046038 9.32 XDH HPRT1
11 urate metabolic process GO:0046415 9.1 SLC2A9 SLC22A12 SLC17A3 SLC17A1 G6PC1 ABCG2

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter activity GO:0022857 9.46 SLC2A9 SLC22A12 SLC17A3 SLC17A1
2 organic anion transmembrane transporter activity GO:0008514 9.4 SLC17A3 ABCG2
3 insulin-like growth factor receptor binding GO:0005159 9.37 REN INS
4 efflux transmembrane transporter activity GO:0015562 9.32 SLC17A3 ABCG2
5 sodium:phosphate symporter activity GO:0005436 9.26 SLC17A3 SLC17A1
6 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A3 SLC17A1
7 urate transmembrane transporter activity GO:0015143 8.92 SLC2A9 SLC22A12 SLC17A3 ABCG2

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....